A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection.

Journal Article (Journal Article)

Full Text

Duke Authors

Vlahovic, Gordana

Cited Authors

Knox, J; Cheng, A; Cleary, S; Galle, P; Kokudo, N; Lencioni, R; Park, J; Zhou, J; Mann, H; Morgan, S; Liu, X; Chin, S; Vlahovic, G; Fan, J

Published Date

July 2019

Published In

Ann Oncol

Volume / Issue

30 Suppl 4 /

Start / End Page

iv51 -

PubMed ID

32085192

Electronic International Standard Serial Number (EISSN)

1569-8041

Digital Object Identifier (DOI)

10.1093/annonc/mdz155.186

Language

eng

Conference Location

England